By Catherine Elton — 2019
The world’s leading advocate for the medicinal use of psychedelics on the ghost of Timothy Leary, why Ecstasy could cure PTSD, and the best place to trip in Boston.
Read on www.bostonmagazine.com
CLEAR ALL
Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.
These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
2
Williams is the co-lead author of a recent retrospective study that found those who tried doses of psilocybin (more commonly known as magic mushrooms), LSD, or MDMA (the pure substance found in Ecstasy or Molly) reported a decrease in trauma symptoms, depression and anxiety after 30 days.
The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found that the former improved symptoms of depression just as well on an established metric—and had fewer side effects.
1
A new review of studies finds that LSD, psilocybin, and MDMA hold potential for treating mental illness.
Study participants at some of the country's leading medical research centers are going through intense therapy and six-hour psychedelic journeys deep into their minds to do things like quit smoking and worry less.
With the advent of the psychedelic renaissance occurring currently, many people have become curious about one of the most famous hallucinogens: psilocybin mushrooms. Read on to discover the most important information about these fascinating fungi.
The latest frontier in state and local drug reform has been the loosening of legal restrictions on psilocybin—the psychoactive compound in “magic mushrooms.”
Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong.
The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).